Table 3 Drug-pathway association in the DTPN of HER2 subtype
Drug | Pathway | nNE and PCI (vs NE = 0.3492) |
|---|---|---|
Fluoracil | Salvage pathways of pyrimidine deoxyribonucleotides | 0.3482 (PCI 0.27%) |
Docetaxel | Epithelial adherens junction signaling | 0.3485 (PCI 0.17%) |
Fulvestrant | Bladder cancer signaling | 0.3473 (PCI 0.51%) |
Methotrexate | Salvage pathways of pyrimidine deoxyribonucleotides | 0.3482 (PCI 0.27%) |
Tamoxifen | Human embryonic stem cell pluripotency (1); regulation of the epithelial-mesenchymal transition (2) | (1) 0.3464 (PCI 0.78%) (2) 0.3490 (PCI 0.02%) (1–2) 0.3462 (PCI 0.84%) |